S'EUDY OF ATRIAL NATRIuRrric PEPTIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COP))
|Full paper||Not Available|
the aim of work In study the changes in plasma atrial natriuretic peptide (ANP) in •. ukliv puln..marv di• '01'1)) :toil In correlate these changes with the \ emit:miry and cardiac 'unctions. Sixt patients with MPH were selected Itom internal medicine and clic'a dep.utinents at lienha I ;111VerSily Hospitals and were classilied into :t pint's. gimp I Hu:Ruled 20 cases on ho•pilal admission ‘vith acute infective exacerbation (group la) and [hest: cases were reinvestieated ô weeks alter medical treatment (Group lb). poop II included taw:. with (019) col pulmonale and right sided hear t failure and rroup III included 'II cases with COPD without cor-pulmonale Their ages ranged from 40 to vcar. old I he•.c ;ilium,: of patient!, weir unmated with 10 healthy !intik-els matched wilh the same age and sex. For all groups, plasma ANP, ventilatory functions and echocardiography were done. The main results of the study, showed that plasma ANP was significantly higher in group la in comparison to group lb . ANP was significantly elevated in all groups, the highest level was in-group In while the lowest level was in-group III. ANP was significantly elevated in group II in comparison to group lb and group III .Also, ANP was correlated with mean pulmonary artery pressure (PAP), surface area of right atrium (SARA), right atrial diameter (RAD), right ventricular diameter (RVD) and right ventricular anterior wall diameter (RVAWD). The decrease of AN? in group lb was associated with improvement in the ventilatory and cardiac functions. We could conclude that; ANP was elevated and correlated with the severity of the disease in COPD cases. Also, it was correlated with the degree of PAP, right atrial and ventricular dimensions. ANP may give a new meaning in the future for the treatment of COPD cases . So, we recommend measurement of it's level in patients with COPD to determine the severity of the disease and follow up it's level during the course of the treatment because it is considered as a good indicator for the improvement of the patient with COPD and the efficacy of the treatment.